跳至主要内容
临床试验/NCT01871233
NCT01871233No Longer Available不适用

An Extended Access Program for Perampanel

Eisai Inc.41 个研究点 分布在 16 个国家开始时间: 2013年6月6日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
No Longer Available
发起方
Eisai Inc.
试验地点
41

研究概览

简要总结

The Extended Access Program (EAP) is a managed access programme for Perampanel. The main objective of this EAP is to ensure that patients participating in studies E2007-A001-207, E2007-G000-307, or E2007-G000-235 continue to have access to perampanel until such time perampanel tablets become commercially available for the treatment of Partial Onset Seizures (POS) in the country in which they reside. This EAP will consist of 2 phases:

  • Screening: The patient will start the program once the Screening assessments are completed and the patient is qualified for participation.
  • Treatment: Additional assessments, physical examinations, and dosage changes will be clinically determined by the treating physician.

Patients will enter this program on the same dose of perampanel that they were receiving at the end of their participation in previous study. Doses of perampanel and of concomitant anti-epileptic drugs (AEDs) can be adjusted (i.e., added,removed, or changed in dose) based on clinical judgment.

Treatment will be prescribed as long as clinically appropriate according to the judgement of the treating physician and the approved Summary of Product Characteristics (SmPC).

The program will complete in a staggered fashion, country by country, as and when perampanel becomes commercially available for the treatment of POS in each country.

研究设计

研究类型
Expanded Access

入排标准

年龄范围
12 Years 至 70 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Patients who are participating in either Study 207, Study 307, or Study 235 and who in the opinion of the treating physician, continue to benefit from treatment with perampanel (revised per Amendment 01)
  • •Patients who provide informed consent where applicable per local requirements.
  • •Female patients of childbearing potential must agree for the duration of the program and for a period of at least 1 month following last dose of perampanel to be abstinent or to commit to the consistent and correct use of a medically acceptable method of birth control (e.g., a double-barrier method [condom plus spermicide, condom plus diaphragm with spermicide])

排除标准

  • •Patients residing in countries where perampanel is commercially available for the treatment of POS
  • •Female patients who are lactating, pregnant, or planning to become pregnant

研究者

发起方
Eisai Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (41)

Loading locations...

相似试验

An Extended Access Program for Perampanel | 临床试验